Special Issue

Novel Approaches for Metabolomics in Drugs and Biomarkers Discovery

Message from the Guest Editor

Metabolomics, by providing a direct vision of the functional metabolic outcome of a given biological system, can enable the discovery of diverse sub-classes of pathophysiological states. This potentiates the discovery of new drug targets and biomarkers, enabling a more precise disease diagnosis and prognosis. The holistic molecular signature captured by metabolomics can also be used to evaluate the effect of drugs and. consequently, to monitor and optimize drug therapies. All of this will contribute towards a more precise and efficient use of medicine. This Special Issue focuses on new approaches in metabolomics enabling the classification of the biological system towards the discovery of drug and disease biomarkers. The topics covered by this Special Issue will include (not exclusively) advances on:

- New methodologies to capture the physiological state of the system.
- Metabolome perturbation according to pathophysiological states.
- Metabolome perturbation due to drugs, and other environmental variables.


Guest Editor

Dr. Cecília R.C. Calado

Department of Chemical Engineering, ISEL—Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, Lisbon, Portugal

Deadline for manuscript submissions

closed (30 June 2024)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/178034

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

